Earnings ·
Karyopharm Therapeutics Inc. reported second quarter 2026 financial results with total revenue of $33.4 million and…
KPTIKaryopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. reported second quarter 2026 financial results with total revenue of $33.4 million and U.S. XPOVIO net product revenue of $30.8 million, compared to $37.9 million and $29.7 million respectively in the prior year period. The company reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million and U.S. XPOVIO net product revenue guidance of $115 million to $130 million. Karyopharm announced it remains on track to submit a supplemental New Drug Application (sNDA) for selinexor in combination with ruxolitinib for myelofibrosis in August under the Accelerated Approval pathway, following FDA feedback that spleen volume reduction qualifies as a reasonably likely surrogate endpoint. The company is actively evaluating financing opportunities and strategic alternatives to extend its cash runway beyond September 2026, when a $15.8 million term loan payment is due. Karyopharm Therapeutics Inc. operates in the pharmaceutical industry, developing and commercializing novel cancer therapies.